Format

Send to:

Choose Destination
See comment in PubMed Commons below
Proc Natl Acad Sci U S A. 2014 May 27;111(21):E2219-28. doi: 10.1073/pnas.1400958111. Epub 2014 May 12.

Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia.

Author information

  • 1Department of Laboratory Medicine andDepartment of Oncology, Hematology and Stem Cell Transplantation, Rheinisch-Westfaelische Technische Hochschule Aachen University Medical School, 52070 Aachen, Germany;
  • 2Department of Laboratory Medicine and.
  • 3Division of Hematology-Oncology, University of California, San Francisco, CA 94143;
  • 4Children's Hospital Los Angeles, Los Angeles, CA 90027;
  • 5Departments of Medicine andPharmacology, Weill Cornell Medical College, New York, NY 10065;
  • 6Cedars Sinai Medical Center, Los Angeles, CA 90048; and.
  • 7Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10466.
  • 8Department of Laboratory Medicine and markus.muschen@ucsf.edu.

Abstract

The unfolded protein response (UPR) pathway, a stress-induced signaling cascade emanating from the endoplasmic reticulum (ER), regulates the expression and activity of molecules including BiP (HSPA5), IRE1 (ERN1), Blimp-1 (PRDM1), and X-box binding protein 1 (XBP1). These molecules are required for terminal differentiation of B cells into plasma cells and expressed at high levels in plasma cell-derived multiple myeloma. Although these molecules have no known role at early stages of B-cell development, here we show that their expression transiently peaks at the pre-B-cell receptor checkpoint. Inducible, Cre-mediated deletion of Hspa5, Prdm1, and Xbp1 consistently induces cellular stress and cell death in normal pre-B cells and in pre-B-cell acute lymphoblastic leukemia (ALL) driven by BCR-ABL1- and NRAS(G12D) oncogenes. Mechanistically, expression and activity of the UPR downstream effector XBP1 is regulated positively by STAT5 and negatively by the B-cell-specific transcriptional repressors BACH2 and BCL6. In two clinical trials for children and adults with ALL, high XBP1 mRNA levels at the time of diagnosis predicted poor outcome. A small molecule inhibitor of ERN1-mediated XBP1 activation induced selective cell death of patient-derived pre-B ALL cells in vitro and significantly prolonged survival of transplant recipient mice in vivo. Collectively, these studies reveal that pre-B ALL cells are uniquely vulnerable to ER stress and identify the UPR pathway and its downstream effector XBP1 as novel therapeutic targets to overcome drug resistance in pre-B ALL.

PMID:
24821775
[PubMed - indexed for MEDLINE]
PMCID:
PMC4040579
Free PMC Article

Publication Types, MeSH Terms, Substances, Secondary Source ID, Grant Support

Publication Types

MeSH Terms

Substances

Secondary Source ID

Grant Support

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk